Löwenberg Mark, de Boer Nanne Kh, Hoentjen Frank
Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.
Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, the Netherlands.
Clin Exp Gastroenterol. 2014 Mar 12;7:53-9. doi: 10.2147/CEG.S48741. eCollection 2014.
The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. However, a proportion of UC patients for whom therapy with anti-TNF agents is indicated fail or become intolerant to treatment with infliximab or adalimumab. Hence, there remains an unmet need for novel anti-TNF agents. Golimumab (Simponi®), a human anti-TNF antibody that is administered by monthly subcutaneous injections, is the most recently introduced TNF blocker for the treatment of UC. Here, we will discuss recent literature on clinical efficacy and safety of golimumab induction and maintenance treatment in patients with UC. Furthermore, we will discuss the positioning of golimumab for UC in current treatment algorithms.
抗肿瘤坏死因子（TNF）治疗性抗体的引入对溃疡性结肠炎（UC）的治疗产生了重大影响。英夫利昔单抗和阿达木单抗是用于诱导UC缓解和维持治疗的强效药物，且具有可接受的安全性。然而，一部分适合使用抗TNF药物治疗的UC患者对英夫利昔单抗或阿达木单抗治疗无效或不耐受。因此，对新型抗TNF药物仍有未满足的需求。戈利木单抗（Simponi®）是一种人源抗TNF抗体，通过每月皮下注射给药，是最近引入的用于治疗UC的TNF阻滞剂。在此，我们将讨论关于戈利木单抗在UC患者中诱导和维持治疗的临床疗效和安全性的近期文献。此外，我们还将讨论戈利木单抗在当前UC治疗方案中的定位。
